Malaria treatment developed using synthetic biology, fermentation
February 28th, 2009 - 2:52 pm ICT by ANIWashington, Feb 28 (ANI): Achieving a milestone in the fight against malaria, scientists at Amyris Biotechnologies have produced 25 g/L of amorphadiene, a precursor of the antimalarial agent artemisinin, by using synthetic biology and E. coli fermentations.
It was in 2003 that the production of amorphadiene in E. coli was first described, but the amount produced was low (50 mg/L). The level was increased to 0.5g/L in 2006, but still 50-fold lower than target production levels.
In the new study, researchers have described the interplay of industrial fermentation processes and synthetic biology that achieve the required 50-fold increase in production levels.
This milestone acts as proof of concept that microbes for conversion to artemisinin can produce commercially relevant concentrations of artemisinin precursors.
The World Health Organization considers artemisinin-based combination therapies (ACTs) to be first-line treatment for malaria.
But, as the supplies of plant-derived artemisinin are subject to the seasonality and volatility common to many plant-based commodities, it leads to fluctuations in the price of artemisinin.
Commercial scale production of semi-synthetic artemisinin would have the potential to stabilize supply and supplement existing plant-derived materials to create a consistent, high-quality and affordable new source of artemisinin to help meet the projected world-wide demand for ACTs.
Originally, the microbial production of Artemisinin precursors was demonstrated in the lab of Professor Jay Keasling at the University of California, Berkeley.
Then Keasling continued the research and founded Amyris to bring the technology to the developing world.
Dr. Jack Newman, a former Post-doc in the Keasling lab and co-founder of Amyris, praised the collaboration effort and the potential of the technology.
“The enormous amount of work involved on the road from idea through execution is mind-boggling. I”m grateful to the dedicated team of researchers, philanthropists and visionaries that made this happen. They have demonstrated the potential of this technology to make a difference in the world, he said
The article, “High-level production of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli” appears in PLoS ONE, an open-access journal from the Public Library of Science. (ANI)
- Resistance to malaria drug rings alarm bells - Apr 08, 2012
- Tweaked E coli can produce low-cost fuel - Jan 28, 2010
- Synthetic biology can prolong anti-malaria drug effectiveness - Mar 07, 2009
- Scientists develop microbe that produces fuels directly from biomass - Jan 28, 2010
- Novel anti-malarial drug candidate discovered - Sep 03, 2010
- Boosting availability of potent anti-malaria drug - Jan 18, 2012
- East Africa's antimalarial trees at risk of extinction - Apr 21, 2011
- Synthetic biology may provide 500 million malaria patients drugs at a 10th of current cost - Jun 04, 2008
- Natural compounds could pave way for novel anti-malaria drugs - Mar 15, 2011
- Canadian researchers announce breakthrough in malaria treatment - Mar 19, 2011
- Engineered plants 'could be turned into green plastics someday' - Nov 09, 2010
- New gene study paves way for more anti-malaria treatments - Oct 11, 2010
- Lucas to market US firm's lubricants in India - Jun 07, 2011
- Bioengineers develop bacterial strain to hike ethanol biofuel production - Dec 10, 2010
- Now, a cheap and organic drug treatment for malaria - Aug 17, 2010
Tags: amyris biotechnologies, artemisinin, combination therapies, developing world, dr jack newman, e coli, fermentation processes, fermentations, jay keasling, malaria treatment, microbes, microbial production, post doc, professor jay, proof of concept, seasonality, study researchers, target production, university of california berkeley, world health organization
